The test is designed to replace multiple testing protocols for acute myeloid leukemia and myelodysplastic syndromes with a seven-day turnaround time.
Caris Life Sciences announced the launch of Caris ChromoSeq, a whole genome sequencing and whole transcriptome sequencing assay designed to support the clinical genomic evaluation of myeloid malignancies.
The test is intended for use in acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. It is also indicated for patients with suspected myeloid malignancies characterized by unexplained cytopenia persisting for more than four months where other potential causes have been reasonably excluded.
Myeloid malignancies are among the most genetically complex cancers, often requiring multiple tests to identify clinically relevant mutations, structural variants, and chromosomal abnormalities. This fragmented approach can delay critical treatment decisions and miss detection of important genomic alterations used for diagnosis and risk stratification.
Caris ChromoSeq is designed to replace multiple test protocols in the myeloid diagnostic workflow, complementing the clinician’s overall clinical and pathological evaluation. The assay delivers approximately 250x read depth across the genome with 40 million transcriptome reads, using bone marrow aspirate or peripheral blood collections.
“The Caris ChromoSeq launch provides an unprecedented amount of genomic and transcriptomic data per patient, enabling a complete diagnostic evaluation in a single test. Never before have patients and physicians had access to a technology with the depth and breadth provided by Caris ChromoSeq,” says Matthew Oberley, MD, PhD, senior vice president, chief clinical officer, and pathologist-in-chief at Caris, in a release. “This launch reflects our commitment to delivering a single, integrated genomic solution for patients with hematological cancers that fits into real‑world clinical workflows and provides results fast enough to inform patient care.”
Results from the assay are synthesized into a single report to support clinical decision-making, with an expected seven-day turnaround time. The launch of the assay follows the company’s focus on molecular profiling technologies to support clinicians across the cancer care continuum.
ID 187057966 © Josepalbert13 | Dreamstime.com
Related Reading:
NeoGenomics Launches New Sequencing Assay for Rapid Genetic Profiling of AML
FDA-Approved MI Cancer Seek Test Enhances Tumor Profiling for Precision Oncology
Precipio and Memorial Sloan-Kettering Publish Study on BCR::ABL1 Assay for Leukemia Monitoring
